Compare CWCO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | ADCT |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | Cayman Islands | Switzerland |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.8M | 484.4M |
| IPO Year | N/A | 2020 |
| Metric | CWCO | ADCT |
|---|---|---|
| Price | $37.62 | $4.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $7.60 |
| AVG Volume (30 Days) | 74.0K | ★ 651.6K |
| Earning Date | 03-16-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $130,832,698.00 | $75,209,000.00 |
| Revenue This Year | $5.00 | $12.48 |
| Revenue Next Year | $37.71 | $5.12 |
| P/E Ratio | $34.44 | ★ N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $22.69 | $1.05 |
| 52 Week High | $39.12 | $4.80 |
| Indicator | CWCO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 60.09 |
| Support Level | $36.50 | $3.66 |
| Resistance Level | $38.74 | $4.10 |
| Average True Range (ATR) | 1.03 | 0.26 |
| MACD | -0.14 | 0.03 |
| Stochastic Oscillator | 33.90 | 89.95 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).